Related Experiment Video
Updated: May 28, 2025

Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet
Published on: November 4, 2015
Sex-Specific Differences in Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty
Paweł Kurzyna1,2, Anna Witowicz3, Piotr Kędzierski1
1Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, European Health Center Otwock, Centre of Postgraduate Medical Education, ERN-LUNG Member, 05-400 Otwock, Poland.
Insights
Women with chronic thromboembolic pulmonary hypertension (CTEPH) present with worse baseline hemodynamics but show superior response to balloon pulmonary angioplasty (BPA) compared to men. This suggests potential sex-specific differences in CTEPH management.
Area of Science:
- Cardiovascular Medicine
- Pulmonary Hypertension Research
- Interventional Cardiology
Background:
- Sex-specific differences in cardiovascular diseases are recognized, yet under-researched in chronic thromboembolic pulmonary hypertension (CTEPH).
- Limited data exists on sex-based outcomes following balloon pulmonary angioplasty (BPA) for CTEPH.
Purpose of the Study:
- To investigate and compare sex-specific differences in CTEPH patients undergoing BPA treatment.
- To evaluate hemodynamic and clinical outcomes between men and women post-BPA.
Main Methods:
- Retrospective analysis of 94 CTEPH patients treated with BPA.
- Assessment of hemodynamic and clinical parameters at baseline and 3 months post-BPA.
Main Results:
- Women exhibited higher baseline systolic pulmonary arterial pressure (sPAP) and pulmonary vascular resistance than men.
- Post-BPA, women showed improved sPAP, pulmonary capillary wedge pressure, and cardiac index.
- Women achieved a greater reduction in mean pulmonary artery pressure and better Dyspnea Borg Scale scores.
Conclusions:
- Women with CTEPH present with more severe baseline hemodynamic compromise but experience better outcomes after BPA.
- Women appear to have better disease adaptation and response to BPA compared to men.
- Further research is warranted to determine if sex-differentiated management strategies are beneficial for CTEPH patients.
Abstract:
Background/Objectives: Several studies describe the sex-specific differences in cardiovascular diseases. However, there is still limited research reporting the difference between men and women with chronic thromboembolic pulmonary hypertension (CTEPH) treated with balloon pulmonary angioplasty (BPA). The aim of this study was to evaluate sex-specific differences in patients with CTEPH treated with BPA. Methods: This retrospective study included CTEPH patients treated with BPA. The patients' hemodynamic and clinical parameters were assessed at baseline and 3 months after completion of BPA treatment. Results: This study included 94 patients (44 women, 46.8%). At baseline, women had higher systolic pulmonary arterial pressure (sPAP) (76 ± 18.5 vs. 85 ± 17.6 mmHg; p = 0.03) and pulmonary vascular resistance (8.21 [5.55-10.17] vs. 9.89 [6.31-14.06] Wood Units; p = 0.03) compared to men. There were no differences in clinical characteristics between the sexes. At follow-up, women had lower sPAP (49 [41-54] vs. 43 [37-49] mmHg; p = 0.04) and pulmonary capillary wedge pressure (10 [9-14] vs. 9 [8-11] mmHg; p = 0.03), but a higher cardiac index (2.57 ± 0.53 vs. 2.82 ± 0.50 L/min/m2; p = 0.03), as well as better Dyspnea Borg Scale outcomes, compared to men. Women had a greater reduction in mean pulmonary artery pressure (-43% vs. -37%; p = 0.049) than men. Conclusions: At baseline, women with CTEPH had worse hemodynamic parameters than men despite similar clinical symptoms. However, the hemodynamic status of women was better after BPA therapy. Hence, women seem better adapted to the disease at baseline and respond better to BPA. Further data are needed to investigate whether the management of CTEPH patients should be sex-differentiated.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...

